ASCO 2021 | Checkmate577: nivolumab in EC/GEJC

Ronan J. Kelly, MD, MBA, Baylor Scott & White Health, Dallas, Texas, discusses the expanded efficacy and safety analysis from Checkmate 577; a Phase III study of adjuvant nivolumab in patients with esophageal and gastroesophageal junction cancer (EC/GEJC) who have residual pathologic disease after receiving neoadjuvant chemoradiotherapy (NCT02743494). Adjuvant nivolumab demonstrated clinically significant efficacy and safety profiles; the primary endpoint of disease-free survival (DFS) was met, with DFS doubling and being maintained across subgroups, the risk of recurrence or death was decreased by 30%, median distant metastasis-free survival increased by 11 months, distant and loco-regional recurrences were reduced in frequency, progression-free survival 2 (PFS2) was improved, treatment was well-tolerated and safe. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.